Merck & Co. signs a licensing agreement with the UN-backed Medicines Patent Pool that will allow more companies to manufacture generic versions of its experimental oral antiviral COVID-19 treatment molnupiravir with a royalty-free license that will apply to 105 low- and middle-income countries.
Merck & Co. signs an licensing agreement with the UN-backed Medicines Patent Pool that will allow more companies to manufacture generic versions of its experimental oral antiviral COVID-19 treatment named molnupiravir with royalty-free license apply to 105 low- and middle-income countries.
Merck & Co. signs a licensing agreement with the UN-backed Medicines Patent Pool that will allow more companies to manufacture generic versions of its experimental oral antiviral COVID-19 treatment molnupiravir with aroyalty-free licensethatwill apply to 105 low- and middle-income countries.
